Aurinia Pharmaceuticals Inc (AUPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 11:04 AM ET
Aurinia Pharmaceuticals Inc (AUPH) Earnings: Report Dates and Results
Aurinia Pharmaceuticals (AUPH) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Aurinia Pharmaceuticals reported EPS of $0.23, above the $0.20 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AUPH has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.4% below the $0.26 reported for the quarter ended Dec 31, 2025.
AUPH Earnings Call
The latest AUPH earnings call transcript on file is labeled 2025Q4.
Read the 2025Q4 transcriptEarnings History
Of the 40 quarters below that had an estimate, AUPH beat 24, missed 13 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $83.70M, up 13.9% from $73.47M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.23 | $0.20 | N/A | +15.00% | Beat | 0.0% | 5 | 1 up, 2 down | Oct 30, 2026 | $83.70M |
| Jun 30, 2026 | $0.28 | $0.18 | N/A | +55.56% | Beat | +75.0% | 5 | N/A | Aug 6, 2026 | $83.22M |
| Mar 31, 2026 | $0.25 | $0.16 | $0.16 - $0.25 | +56.25% | Beat | +56.3% | 4 | 0 up, 1 down | May 7, 2026 | $77.70M |
| Dec 31, 2025 | $0.26 | $0.21 | $0.18 - $0.26 | +23.81% | Beat | +2500.0% | 6 | 1 up, 0 down | Feb 26, 2026 | $77.11M |
| Sep 30, 2025 | $0.23 | $0.16 | $0.10 - $0.21 | +43.75% | Beat | +130.0% | 6 | 2 up, 0 down | Nov 4, 2025 | $73.47M |
| Jun 30, 2025 | $0.16 | $0.15 | $0.11 - $0.20 | +6.67% | Beat | +1500.0% | 6 | 1 up, 1 down | Jul 31, 2025 | $70.01M |
| Mar 31, 2025 | $0.16 | $0.10 | $0.07 - $0.14 | +60.00% | Beat | N/A | 5 | 0 up, 1 down | May 12, 2025 | $62.47M |
| Dec 31, 2024 | $0.01 | -$0.02 | -$0.09 - $0.16 | +162.50% | Beat | N/A | 5 | 0 up, 0 down | Feb 27, 2025 | $59.87M |
| Sep 30, 2024 | $0.10 | $0.02 | -$0.04 - $0.05 | +400.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2024 | $67.77M |
| Jun 30, 2024 | $0.01 | $0.01 | -$0.04 - $0.07 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Aug 1, 2024 | $57.19M |
| Mar 31, 2024 | -$0.07 | -$0.14 | -$0.20 - $0.01 | +50.00% | Beat | N/A | 6 | 0 up, 0 down | May 2, 2024 | $50.30M |
| Dec 31, 2023 | -$0.19 | -$0.16 | -$0.24 - -$0.14 | -18.75% | Miss | N/A | 6 | 0 up, 1 down | Feb 15, 2024 | $45.09M |
| Sep 30, 2023 | -$0.09 | -$0.17 | -$0.19 - -$0.13 | +47.06% | Beat | N/A | 7 | 0 up, 0 down | Nov 2, 2023 | $54.52M |
| Jun 30, 2023 | -$0.08 | -$0.19 | -$0.22 - -$0.16 | +57.89% | Beat | N/A | 6 | 0 up, 0 down | Aug 3, 2023 | $41.49M |
| Mar 31, 2023 | -$0.18 | -$0.22 | -$0.25 - -$0.18 | +18.18% | Beat | N/A | 7 | 0 up, 1 down | May 4, 2023 | $34.41M |
| Dec 31, 2022 | -$0.18 | -$0.27 | -$0.33 - -$0.24 | +33.33% | Beat | N/A | 7 | 1 up, 0 down | Feb 28, 2023 | $28.43M |
| Sep 30, 2022 | -$0.06 | -$0.19 | -$0.25 - $0.00 | +68.42% | Beat | N/A | 7 | 0 up, 0 down | Nov 3, 2022 | $55.78M |
| Jun 30, 2022 | -$0.25 | -$0.22 | -$0.25 - -$0.19 | -13.64% | Miss | N/A | 6 | 0 up, 0 down | Aug 4, 2022 | $28.19M |
| Mar 31, 2022 | -$0.27 | -$0.27 | -$0.29 - -$0.24 | 0.00% | In line | N/A | 7 | 0 up, 1 down | May 10, 2022 | $21.63M |
| Dec 31, 2021 | -$0.25 | -$0.27 | -$0.30 - -$0.24 | +7.41% | Beat | N/A | 7 | N/A | Feb 28, 2022 | $23.40M |
| Sep 30, 2021 | -$0.39 | -$0.33 | -$0.38 - -$0.30 | -18.18% | Miss | N/A | 7 | N/A | Nov 3, 2021 | $14.67M |
| Jun 30, 2021 | -$0.37 | -$0.36 | N/A | -2.78% | Miss | N/A | N/A | 0 up, 0 down | Aug 5, 2021 | $6.62M |
| Mar 31, 2021 | -$0.40 | -$0.38 | N/A | -5.26% | Miss | N/A | N/A | N/A | May 6, 2021 | $914000 |
| Dec 31, 2020 | -$0.05 | -$0.24 | N/A | +79.17% | Beat | N/A | N/A | N/A | Feb 24, 2021 | $50.03M |
| Sep 30, 2020 | -$0.30 | -$0.24 | N/A | -25.00% | Miss | N/A | N/A | N/A | Nov 10, 2020 | $29000 |
| Jun 30, 2020 | -$0.26 | -$0.24 | N/A | -8.33% | Miss | N/A | N/A | N/A | Aug 11, 2020 | $29000 |
| Mar 31, 2020 | -$0.23 | -$0.34 | N/A | +32.35% | Beat | N/A | N/A | N/A | May 14, 2020 | $30000 |
| Dec 31, 2019 | -$0.78 | -$0.21 | N/A | -271.43% | Miss | N/A | N/A | N/A | Mar 5, 2020 | $29000 |
| Sep 30, 2019 | -$0.21 | -$0.18 | N/A | -16.67% | Miss | N/A | N/A | N/A | Nov 14, 2019 | $230000 |
| Jun 30, 2019 | -$0.17 | -$0.17 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 6, 2019 | $29000 |
| Mar 31, 2019 | -$0.16 | -$0.18 | N/A | +11.11% | Beat | N/A | N/A | N/A | May 14, 2019 | $30000 |
| Dec 31, 2018 | -$0.17 | -$0.18 | N/A | +5.56% | Beat | N/A | N/A | N/A | Jan 22, 2019 | $29000 |
| Sep 30, 2018 | -$0.21 | -$0.19 | N/A | -10.53% | Miss | N/A | N/A | N/A | Nov 8, 2018 | $375000 |
| Jun 30, 2018 | -$0.16 | -$0.17 | N/A | +5.88% | Beat | N/A | N/A | N/A | Aug 9, 2018 | $29000 |
| Mar 31, 2018 | -$0.15 | -$0.17 | -$0.20 - -$0.13 | +11.76% | Beat | N/A | 4 | N/A | May 10, 2018 | $30000 |
| Dec 31, 2017 | -$0.04 | -$0.14 | -$0.19 - -$0.08 | +71.43% | Beat | N/A | 6 | N/A | Mar 15, 2018 | $31000 |
| Sep 30, 2017 | -$0.16 | -$0.12 | -$0.22 - -$0.12 | -33.33% | Miss | N/A | 4 | N/A | Nov 14, 2017 | $29000 |
| Jun 30, 2017 | -$0.12 | -$0.13 | -$0.14 - -$0.08 | +7.69% | Beat | N/A | 4 | N/A | Aug 10, 2017 | $329000 |
| Mar 31, 2017 | -$0.20 | -$0.12 | -$0.15 - -$0.08 | -66.67% | Miss | N/A | 6 | N/A | May 15, 2017 | $31000 |
| Dec 31, 2016 | -$0.21 | -$0.11 | N/A | -90.91% | Miss | N/A | N/A | N/A | Jan 3, 2017 | $30000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.81, up 1520.0% from the year before. It was -$0.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.81 | +1520.0% |
| Dec 31, 2024 | $0.05 | N/A |
| Dec 31, 2023 | -$0.54 | N/A |
| Dec 31, 2022 | -$0.76 | N/A |
| Dec 31, 2021 | -$1.41 | N/A |
| Dec 31, 2020 | -$0.84 | N/A |
| Dec 31, 2019 | -$1.32 | N/A |
| Dec 31, 2018 | -$0.69 | N/A |
| Dec 31, 2017 | -$0.52 | N/A |
| Dec 31, 2016 | -$0.65 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 4,700 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q4 | Dec 31, 2025 | 4,658 | 10 | |
| 2025Q3 | Sep 30, 2025 | 3,714 | 11 | |
| 2025Q2 | Jun 30, 2025 | 3,565 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,029 | 11 | |
| 2024Q4 | Dec 31, 2024 | 3,860 | 10 | |
| 2024Q3 | Sep 30, 2024 | 3,830 | 9 | |
| 2024Q2 | Jun 30, 2024 | 6,368 | 9 |
2025Q4 Earnings Call
Opening remarks
Peter Greenleaf CEO Good morning. We want to thank you all for joining us today to discuss Aurinia's Fourth Quarter and Full Year 2025 Update. Joining me on the call today are Joe Miller, our Chief Financial Officer; and Dr. Greg Keenan, our Chief Medical Officer. On today's call, we will report fourth quarter and full year 2025 financial results and provide an update on recent business progress. During today's call, we may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. We are pleased to have delivered strong LUPKYNIS sales in 2025, growing at a rate of 25% year-over-year. And for 2026, we expect net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. And with that introduction, I'd like to now turn the call over to Joe to review our financial results. Joe?
Joseph Miller CFO Thank you, Peter. Total revenue for the fourth quarter of 2025 was $77.1 million, up 29% compared to $59.9 million for the same period of 2024. Net product sales of LUPKYNIS for the fourth quarter of 2025 were $74.2 million, up 29% compared to $57.6 million in 2024. Net income for the fourth quarter of 2025 was $210.8 million, up 14,957% from $1.4 million in 2024. In the fourth quarter of 2025, the company recorded an income tax benefit of $175.1 million, primarily due to the release of its valuation allowance on deferred tax assets that the company now expects to realize. Net income before income taxes for the fourth quarter of 2025 was $35.7 million, up 2,875% from $1.2 million in 2024. Diluted earnings per share for the fourth quarter of 2025 was $1.53, up 15,200% from $0.01 in 2024. Lastly, cash flows from operating activities for the fourth quarter of 2025 were $45.7 million, up 52% from $30.1 million in 2024. Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% compared to the $235.1 million for the same period of 2024. As a reminder, the 2024 period included a milestone payment of $10 million associated with LUPKYNIS regulatory approval in Japan. Excluding the one-time milestone, total revenue increased by 26% over the same period in 2024. Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024. Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024.
Frequently Asked Questions About AUPH
When is Aurinia Pharmaceuticals's next earnings date?
Aurinia Pharmaceuticals's next earnings report is expected for Feb 24, 2027.
Did AUPH beat earnings estimates last quarter?
Yes. Aurinia Pharmaceuticals reported EPS of $0.23 for the quarter ended Sep 30, 2026, above the $0.20 estimate, a 15.00% surprise.
What EPS do analysts expect from AUPH next quarter?
The consensus EPS estimate for Aurinia Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.22 from 7 analysts, with estimates from $0.17 to $0.25.
How often does AUPH beat earnings estimates?
Aurinia Pharmaceuticals beat the EPS estimate in each of the last 9 quarters, with an average surprise of +91.50%.
AUPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors